Valuation : Harrow, Inc.

Market Cap 1.47B 1.27B 1.18B 1.08B 2.04B 141B 2.05B 14.03B 5.48B 70.97B 5.54B 5.42B 235B P/E 2026 *
-621x
P/E 2027 * 17.5x
Enterprise Value 1.47B 1.27B 1.18B 1.08B 2.04B 141B 2.05B 14.03B 5.48B 70.97B 5.54B 5.42B 235B EV / Sales 2026 *
4.2x
EV / Sales 2027 * 2.77x
Free-Float
84.62%
Yield 2026 *
-
Yield 2027 * -
1 day-1.60%
1 week-7.77%
Current month+0.05%
1 month+3.55%
3 months+12.66%
6 months-28.41%
Current year-20.84%
1 week 38.15
Extreme 38.15
42.7
1 month 36.25
Extreme 36.25
43
Current year 28.54
Extreme 28.5401
54.85
1 year 28.54
Extreme 28.5401
54.85
3 years 7.6
Extreme 7.6
59.23
5 years 5.4
Extreme 5.4
59.23
10 years 1.35
Extreme 1.35
59.23
Manager TitleAgeSince
Chief Executive Officer 53 2011-12-16
President 43 2025-08-20
Compliance Officer - 2023-09-30
Director TitleAgeSince
Chairman 53 2021-08-18
Director/Board Member 57 2022-03-30
Director/Board Member 71 2024-01-25
Date Insider Type Main position Quantity % Market Cap.
8/14/26 Fiscal year

Chief Technology Officer

33,750 0.0905%
2/27/26
Opaleye Management, Inc.
SellCompany 5,000 0.0135%
1/30/26 Free

CHIEF COMMERCIAL OFFICER

40,000 0.1080%
Change 5-day change 1-year change 3-year change Capi.($)
-1.60%-7.77%0.00%+145.35% 1.47B
-0.55%-4.88%+61.23%+113.70% 1,060B
-1.62%-0.22%+50.91%+62.39% 651B
-1.98%-1.40%+24.08%+75.11% 465B
-1.17%-2.10%+38.61%+40.46% 365B
-2.00%-1.35%+22.22%+37.78% 300B
-0.98%+0.53%+2.04%+12.13% 258B
-0.39%+1.32%+52.60%+71.29% 238B
-3.18%-0.30%-17.23%-54.33% 210B
-0.15%+3.38%+30.17%+92.48% 184B
Average -1.30%-0.14%+26.46%+59.64% 373.19B
Weighted average by Cap. -1.20%-2.15%+38.84%+66.46%

Financials

2026 *2027 *
Net sales 351M 301M 282M 258M 486M 33.5B 488M 3.34B 1.3B 16.88B 1.32B 1.29B 55.87B 533M 457M 428M 392M 738M 50.86B 740M 5.07B 1.98B 25.63B 2B 1.96B 84.84B
Net income -2.27M -1.95M -1.82M -1.67M -3.14M -216M -3.15M -21.57M -8.43M -109M -8.51M -8.33M -361M 89.19M 76.56M 71.68M 65.63M 124M 8.52B 124M 849M 332M 4.29B 335M 328M 14.21B
Net Debt - -
Logo Harrow, Inc.
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Employees
373
Date Price Change Volume
26-08-27 US$38.79 -1.37% 221,127
26-08-26 US$39.33 -4.84% 566,988
26-08-25 US$41.33 +3.84% 472,368
26-08-24 US$39.80 -2.81% 419,014
26-08-21 US$40.95 -2.64% 466,462
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
39.33USD
Average target price
67.50USD
Spread / Average Target
+71.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HROW Stock